<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INAMRINONE LACTATE <img border="0" src="../images/pr.gif"/></span><br/>(in-am'ri-none)<br/><span class="topboxtradename">Inocor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">inotropic agent</span>; <span class="classification">vasodilator</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>A new chemical class of cardiac inotropic agents with vasodilator activity. Mode of action appears to differ from that of
         the digitalis glycosides and beta-adrenergic stimulants. In patients with depressed myocardial function, it enhances myocardial
         contractility, increases cardiac output and stroke volume, and reduces right and left ventricular filling pressure, pulmonary
         capillary wedge pressure (PCWP), and systemic vascular resistance.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It reduces afterload and preload by its direct relaxant effect on vascular smooth muscle. Inamrinone produces hemodynamic
         improvements and symptomatic relief in patients in CHF due to ischemic heart disease.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of CHF in patients not adequately controlled by traditional therapy, such as digitalis, diuretics, and
         vasodilators, and may be used in conjunction with these agents.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to inamrinone or to bisulfites; severe aortic or pulmonic valvular disease in lieu of appropriate surgery,
         acute MI; uncorrected hypokalemia or dehydration. Safe use during pregnancy (category C), lactation, or children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Compromised renal or hepatic function, arrhythmias, hypertrophic subaortic stenosis; decreased platelets. Concomitant cardiac
         glycoside therapy recommended in patients with atrial flutter or fibrillation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Congestive Heart Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.75 mg/kg bolus given slowly over 23 min, then start infusion at 510 mcg/kg/min, may repeat bolus in 30 min (max:
               10 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span> Give loading dose undiluted or diluted by adding 1 mL of NS or 0.45% NS to each 5 mg (1 mL).  <span class="methodtype"> IV Infusion:</span>  Dilute 300 mg (60 mL) in 60 mL of NS or 0.45% NS to yield 2.5 mg/mL. Natural color is clear yellow. Discard discolored solutions and those with precipitate. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give loading dose over 23 min. May inject into a running D5W infusion through Y-connector or directly.  <span class="methodtype">IV Infusion:</span>  Give diluted solution at a rate of 510 mg/kg/min. Use infusion pump to regulate rate. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Sodium bicarbonate,</b> <b>dextrose</b>-containing solutions. <span class="incompattype">Y-site:</span> <b>Furosemide.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Use all diluted solutions within 24 h.</li>
<li>Protect ampules from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (pericarditis, pleuritis; myositis with interstitial shadows on chest x-ray and elevated sedimentation rate;
      vasculitis with nodular pulmonary densities, hypoxemia, ascites, jaundice). <span class="typehead">CV:</span> Hypotension, arrhythmias. <span class="typehead">Endocrine:</span> Nephrogenic diabetes insipidus. <span class="typehead">GI:</span> Nausea, vomiting, anorexia, abdominal cramps, hepatotoxicity. <span class="typehead">Hematologic:</span> Asymptomatic thrombocytopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Possibility of excessive hypotension with disopyramide. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  25 min. <span class="typehead">Peak:</span> 10 min. <span class="typehead">Duration:</span> About 2 h. <span class="typehead">Distribution:</span> Unknown if it crosses placenta or into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 3.67.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Increased cardiac output, decreased PCWP, relief of symptoms of CHF. Central venous
            pressure may be used to assess hypotension and blood volume.
         </li>
<li>Monitor BP, heart rate, and respirations and keep physician informed. Rate of administration and duration of therapy are prescribed
            according to clinical response and adverse effects.
         </li>
<li>Consult physician for guidelines. In general, rate of infusion should be slowed or stopped with excessive drop in BP or arrhythmias.</li>
<li>Monitor infusion site to prevent extravasation.</li>
<li>Monitor I&amp;O ratio and pattern and daily weights. Improvement in cardiac output enhances diuresis with consequent danger of
            hypokalemia and arrhythmias, particularly in digitalized patients.
         </li>
<li>Lab tests: Monitor closely platelet counts, liver enzymes, fluid and electrolyte balances, renal function.</li>
<li>Correct hypokalemia before and during therapy.</li>
<li> 							Note: If platelet count falls below 150,000/mm<sup>3</sup>, report immediately to physician; may indicate thrombocytopenia. 						
         </li>
<li>Allergy alert: IV preparation contains sodium metabisulfite, a reducing agent to which certain susceptible individuals are
            allergic. Discontinue immediately if patient shows hypersensitivity reactions.
         </li>
<li>Observe patient closely when drug is withdrawn after prolonged therapy; clinical deterioration may occur within hours.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>